Skip to main content
Journal cover image

Whole exome sequencing reveals a dual diagnosis of BCAP31-related syndrome and glutaric aciduria III.

Publication ,  Journal Article
Huggins, E; Jackson, DG; Young, SP; Kishnani, PS
Published in: Mol Genet Metab Rep
September 2024

BACKGROUND: Biochemical testing is a common first-tier approach in the setting of genetic evaluation of patients with unexplained developmental delay. However, results can be unclear, and a plan for second-tier analysis must be determined based on the patient's biochemical results and clinical presentation - in many cases, triggering a diagnostic odyssey. CASE PRESENTATION: A male patient from the United States presenting with unexplained developmental delay, microcephaly, hypotonia, and feeding difficulties was referred for clinical genetic evaluation at age 8 months. Biochemical testing revealed an isolated marked elevation of glutaric acid on urine organic acid profile, without elevations of related metabolites. Further testing included GCDH sequencing, a neurometabolic gene panel, chromosomal microarray, Prader Willi/Angelman testing, and lysosomal disease enzyme panel, all of which were non-diagnostic. The patient had persistent developmental delay and hypotonia, dystonia, sensorineural hearing loss, and abnormal brain myelination on magnetic resonance imaging. Whole exome sequencing (WES) was performed and revealed a dual diagnosis of glutaric aciduria III (GA III) and BCAP31-related disorder, an X-linked intellectual disability syndrome, caused by a novel pathogenic variant. CONCLUSIONS: GA III has historically been considered clinically benign, with few reported cases. This patient's presenting symptoms were similar to those commonly seen in GA I and GA II, however the biochemical abnormalities were not consistent with these disorders, prompting additional molecular and biochemical testing. Ultimately, WES confirmed a diagnosis of BCAP31-related syndrome, a rare neurological disorder, which explained the patient's presenting symptoms. WES also identified a secondary diagnosis of GA III. We present a patient with two rare genetic conditions, highlighting the importance of deep phenotyping and the utility of WES in the setting of a patient with dual genetic diagnoses.

Duke Scholars

Published In

Mol Genet Metab Rep

DOI

ISSN

2214-4269

Publication Date

September 2024

Volume

40

Start / End Page

101117

Location

United States

Related Subject Headings

  • 3202 Clinical sciences
  • 3105 Genetics
  • 0604 Genetics
  • 0601 Biochemistry and Cell Biology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Huggins, E., Jackson, D. G., Young, S. P., & Kishnani, P. S. (2024). Whole exome sequencing reveals a dual diagnosis of BCAP31-related syndrome and glutaric aciduria III. Mol Genet Metab Rep, 40, 101117. https://doi.org/10.1016/j.ymgmr.2024.101117
Huggins, Erin, David G. Jackson, Sarah P. Young, and Priya S. Kishnani. “Whole exome sequencing reveals a dual diagnosis of BCAP31-related syndrome and glutaric aciduria III.Mol Genet Metab Rep 40 (September 2024): 101117. https://doi.org/10.1016/j.ymgmr.2024.101117.
Huggins E, Jackson DG, Young SP, Kishnani PS. Whole exome sequencing reveals a dual diagnosis of BCAP31-related syndrome and glutaric aciduria III. Mol Genet Metab Rep. 2024 Sep;40:101117.
Huggins, Erin, et al. “Whole exome sequencing reveals a dual diagnosis of BCAP31-related syndrome and glutaric aciduria III.Mol Genet Metab Rep, vol. 40, Sept. 2024, p. 101117. Pubmed, doi:10.1016/j.ymgmr.2024.101117.
Huggins E, Jackson DG, Young SP, Kishnani PS. Whole exome sequencing reveals a dual diagnosis of BCAP31-related syndrome and glutaric aciduria III. Mol Genet Metab Rep. 2024 Sep;40:101117.
Journal cover image

Published In

Mol Genet Metab Rep

DOI

ISSN

2214-4269

Publication Date

September 2024

Volume

40

Start / End Page

101117

Location

United States

Related Subject Headings

  • 3202 Clinical sciences
  • 3105 Genetics
  • 0604 Genetics
  • 0601 Biochemistry and Cell Biology